Stay updated on Pembrolizumab and Acalabrutinib in NSCLC Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab and Acalabrutinib in NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab and Acalabrutinib in NSCLC Clinical Trial page

  1. Check
    3 days ago
    Change Detected
    Summary
    A site-wide notice announces the NIH website transition and says federal agencies are adopting “Super Intelligence” in place of “Artificial Intelligence.”
    Difference
    1%
    Check dated 2026-10-25T01:58:12.000Z thumbnail image
  2. Check
    10 days ago
    Change Detected
    Summary
    The footer’s site revision changed from v3.7.1 to v3.7.2; the page still displays a 403 Forbidden error instead of the study record.
    Difference
    0.2%
    Check dated 2026-10-18T01:44:42.000Z thumbnail image
  3. Check
    17 days ago
    Change Detected
    Summary
    The site revision label in the page footer changed from v3.7.0 to v3.7.1.
    Difference
    0.2%
    Check dated 2026-10-11T02:08:54.000Z thumbnail image
  4. Check
    38 days ago
    Change Detected
    Summary
    The page now displays a 403 Forbidden error, replacing the previous study record content and navigation, which indicates the study page is currently inaccessible.
    Difference
    17%
    Check dated 2026-09-20T00:49:52.000Z thumbnail image
  5. Check
    59 days ago
    Change Detected
    Summary
    The page’s Revision tag was updated from v3.6.5 to v3.6.6, signaling a new version of the page content or its underlying template.
    Difference
    0.1%
    Check dated 2026-08-29T20:58:22.000Z thumbnail image
  6. Check
    80 days ago
    Change Detected
    Summary
    The page now presents an error page indicating the content is unavailable, including the HTML skeleton and header/footer, which removes the study information and linked documents from view.
    Difference
    16%
    Check dated 2026-08-08T17:46:50.000Z thumbnail image

Stay in the know with updates to Pembrolizumab and Acalabrutinib in NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab and Acalabrutinib in NSCLC Clinical Trial page.